Amifostine + Carboplatin + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapeutic Agent Toxicity
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Trial Timeline
May 1, 2003 → Jun 1, 2008
NCT ID
NCT00095927About Amifostine + Carboplatin + Paclitaxel
Amifostine + Carboplatin + Paclitaxel is a phase 2 stage product being developed by AstraZeneca for Chemotherapeutic Agent Toxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT00095927. Target conditions include Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00095927 | Phase 2 | Completed |